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A SNP (rs8004664) in the first intron of the FOXN3
gene is associated with human fasting blood
glucose. We find that carriers of the risk allele have
higher hepatic expression of the transcriptional
repressor FOXN3. Rat Foxn3 protein and zebrafish
foxn3 transcripts are downregulated during fasting,
a process recapitulated in human HepG2 hepa-
toma cells. Transgenic overexpression of zebrafish
foxn3 or human FOXN3 increases zebrafish hepatic
gluconeogenic gene expression, whole-larval free
glucose, and adult fasting blood glucose and also
decreases expression of glycolytic genes. Hepatic
FOXN3 overexpression suppresses expression of
mycb, whose orthologMYC is known to directly stim-
ulate expression of glucose-utilization enzymes. Car-
riers of the rs8004664 risk allele have decreasedMYC
transcript abundance. Human FOXN3 binds DNA se-
quences in the humanMYC and zebrafishmycb loci.
We conclude that the rs8004664 risk allele drives
excessive expression of FOXN3 during fasting and
that FOXN3 regulates fasting blood glucose.INTRODUCTION
Approximately 100 genes have been associated with type 2 dia-
betes mellitus, a commonmulti-organ disease marked by strong
but complex genetic propensity (Bonnefond and Froguel, 2015;
Grarup et al., 2014). Most of the genes identified in such popula-
tion-based studies that have been studied mechanistically
appear to act primarily, albeit not exclusively, in the develop-
ment, survival, and function of pancreatic b cells (Bonnefond
and Froguel, 2015; Grarup et al., 2014). Nevertheless, functional
dissection of the contributions of individual genome-wide
association study (GWAS) ‘‘hits’’ is lacking for the majority of
identified associations (Sanghera and Blackett, 2012). Under-
standing how these population genetics-derived findings impact
metabolic regulation holds the promise of developing more
effective diagnostic and therapeutic tools.Cell
This is an open access article under the CC BY-NHere, we examine the basis for the statistically significant and
independent association of the SNP rs8004664, which occurs in
the first intron of human FOXN3, with altered fasting blood
glucose (Manning et al., 2012). FOXN3 interacts with transcrip-
tional repressors and binds DNA through a highly conserved
Forkhead box domain (Pati et al., 1997; Scott and Plon, 2005).
We show that FOXN3 transcript and FOXN3 protein abundance
are increased in primary hepatocytes from carriers of the
rs8004664 risk allele. This risk-allele-linked increase in FOXN3
expression contrasts with the normal downregulation of Rat
Foxn3 protein and zebrafish foxn3 transcripts during fasting, as
well as the rapid decreases in human HepG2 hepatoma cell
FOXN3 protein abundance in minimal medium. To test whether
excessive FOXN3 protein modulates glucose metabolism, we
prepared transgenic zebrafish lines overexpressing zebrafish
foxn3 and human FOXN3. These lines show increased hepatic
gluconeogenic gene expression, decreased hepatic glycolytic
gene expression, increased whole-larval free glucose, and
increased adult fasting blood glucose, all findings suggesting
FOXN3 drives excessive glucose production. To understand
the molecular basis of these findings, we examined the whole
transcriptomes of transgenic animal livers, comparing them to
non-transgenic animals. Hepatic FOXN3 overexpression sup-
presses expression ofmycb, which encodes a MYC family tran-
scription factor whosemouse and human orthologs are known to
directly stimulate expression of multiple glucose-utilization en-
zymes. Carriers of the rs8004664 risk allele had decreased
MYC transcript abundance, suggesting that FOXN3 might
directly inhibit MYC expression. We found human FOXN3 pre-
cipitates DNA sequences within the human MYC and zebrafish
mycb genes. We conclude that the rs8004664 risk allele drives
inappropriate (excessive) expression of FOXN3 during fasting.
We conclude FOXN3 is a pathological regulator of fasting blood
glucose.RESULTS
The rs8004664 Risk Allele Increases Expression of
FOXN3
The rs8004664 SNP resides in the first, large intron of the FOXN3
gene,which has several annotated transcript variants (Figure 1A).
The most-abundant transcript variant FOXN3-T003 encodes theReports 15, 2745–2755, June 21, 2016 ª 2016 The Author(s). 2745
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. The rs8004664 Risk Allele Increases FOXN3 Gene Expression
(A) The 514.28-kb FOXN3 locus is on the reverse strand of human chromosome 14. The -003 transcripts variant encodes the full-length protein. Four other major,
protein-coding transcript variants are annotated in GENCODE 24. Note the location of rs8004664, within the first, large intron. Transcript variant -T001 encodes a
468-aminoacyl residue (aa) protein; -T003 encodes a 490-aa protein; -T004 encodes a 468-aa protein; -T201 encodes a 490-aa protein; and -T202 encodes a
468-aa protein.
(B) Allele frequencies in the 1000 Genomes dataset. ‘‘A’’ is the hyperglycemia risk allele. The overall minor (risk) allele frequency is 30%.
(C) The distance in base pairs of the nearest SNPs in linkage disequilibrium to rs8004664 is shown in the table (left). Linkage disequilibrium (R2 values) and
recombination rate (cM/Mb) plots for the 10-kb flanking the rs8004664 are shown for the entire 1000 Genomes dataset (plotted with SNAP). Note the chro-
mosomal position of rs8004664 is different from that shown in (A) because different builds of the human genome were queried.
(D) Steady-state transcript abundance of FOXN3-T003 and -T004 in cryopreserved human hepatocytes from donors with the indicated rs8004664 genotypes,
GjG (n = 2), AjG (n = 8), and AjA (n = 6). Horizontal lines indicate the median value. Transcript variant -T003 is the most abundant, followed by -T004. Mean ± SEM
values are shown. Ct = 26.9 ± 0.3 for -T003 and 31.7 ± 0.4 cycles for -T004. *p = 0.03; two-tailed Student’s t test.
(legend continued on next page)
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Figure 2. FOXN3 Is Nutritionally Regulated
(A) HepG2 cells were grown in complete medium (0 hr) and then subjected to
nutrient deprivation for the indicated times (all in hours). Where indicated,
samples were returned to complete medium for the indicated time (‘‘+’’), and
RT-PCR was performed to measure FOXN3-T003 and FOXN3-T004 transcript
abundance. Mean ± SEM values are shown. *p < 0.001; one-way ANOVA.
(B and C) Immunoblot analysis and densitometric analysis were performed for
human FOXN3 and TUBB at the times indicated in (A). Mean ± SEM values are
shown. p = 0.06 in one-way ANOVA. n = 3.
(D and E) Foxn3 protein abundancewas quantifiedwith immunoblot analysis of
liver homogenates from fed and fasted rat livers. Mean ± SEM values are
shown. *p = 0.0007; two-tailed Student’s t test.
(F) foxn3 transcript abundance wasmeasured in fed and fasted adult zebrafish
livers. Mean ± SEM values are shown. *p < 0.004; two-tailed Student’s t test.
n = 6.full-length protein. Allele frequencies vary among populations,
with an overall frequency in the 1000 Genomes database of
the hyperglycemia risk allele of 30% (Figure 1B). Over a 100-kb
interval flanking it, rs8004664 appears to be in linkage disequilib-
rium only with nearby (less than 8,000 bp) SNPs (Figures 1C and(E and F) Sufficient protein was retrieved from 12 of the 16 donor liver samples an
FOXN3 transcript, with increasing abundance proportional to the number of rs800
two-tailed Student’s t test. TUBB, b-tubulin.
See also Figure S1 and Table S1.S1). This SNP does not appear to be in a recombination hotspot
nor does it appear to be in an annotated transcription factor
binding site (Motallebipour et al., 2009).
Query of The Human Protein Atlas (Uhle´n et al., 2015), the
largest repository of human immunohistochemical and RNA-
seq data publically available, revealed human FOXN3 protein
and mRNA are not detected in the pancreas but are expressed
in liver and renal tubules. These are both gluconeogenic organs
that participate in maintaining fasting glucose levels. To deter-
mine whether the rs8004664 SNP affects FOXN3 transcript
abundance, we genotyped 16 primary human hepatocyte sam-
ples for the rs8004664 SNP (Table S1). Gene expression analysis
showed that, as compared to the protective allele (G), the
rs8004664 risk allele (A) dose dependently increased the abun-
dance of the dominant FOXN3 transcript variant (-T003) by
nearly two orders of magnitude but did not alter the (far lower)
expression of the next most-abundant transcript variant
FOXN3-T004 (Figure 1D; Table S1). The rs8004664 risk allele
also increased FOXN3 protein expression (Figures 1D and 1E).
FOXN3 Is Normally Downregulated in Fasting
In order to determine whether FOXN3 is metabolically regulated,
changes in gene regulation in response to glucose were
measured by assessing FOXN3 transcript and FOXN3 protein
abundance in humanHepG2 hepatoma cells, which are homozy-
gous for the rs8004664 protective allele (Motallebipour et al.,
2009). Within 2 hr of switching HepG2 cells from a complete me-
dium to a minimal medium (low glucose and no serum), FOXN3-
T003 transcript and FOXN3 protein abundance decreased,
whereas the far-lower abundance FOXN3-T004 transcript did
not (Figure 2A). Furthermore, the acute restoration of complete
medium increased FOXN3 protein abundance to a greater de-
gree than it did FOXN3-T003 transcript abundance (Figures 2B
and 2C). Supporting these findings of acute metabolic regulation
of FOXN3 transcript abundance, we observed that Foxn3 protein
content was increased in livers of fed rats as compared to livers
of fasted rats (Figures 2D and 2E). Likewise, we found that
the livers of fasted adult zebrafish had decreased foxn3 tran-
script abundance compared to the livers of fed adult zebrafish
(Figure 2F).
FOXN3 Overexpression Drives Hepatic Glucose
Production
Zebrafish Foxn3 shares strong sequence homology to human
FOXN3 (Figure 3A). Beyond this narrow primary structure con-
servation, zebrafish models for studying glucose metabolism
have emerged as a powerful approach to answeringmechanistic
questions relating to physiology and gene regulation (Schlegel
and Gut, 2015). Thus, we generated two transgenic zebrafish
lines expressing zebrafish foxn3 and human FOXN3 cDNAs un-
der the control of the constitutively active, liver-specific fabp10a
promoter. The transgenic constructs contained the ‘‘liberated’’alyzed in (D) for immunoblot analysis. FOXN3 protein showed a similar trend as
4664 risk alleles present. Horizontal lines indicate the median value. *p = 0.06;
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Figure 3. FOXN3 Drives Increased Hepatic Glucose Production
(A) Human FOXN3 and zebrafish Foxn3 orthologs are shownwith the central DNA-binding Forkhead box (nearly invariant aminoacyl residues 112–204) and length
marked (to the right). The percent identity of the zebrafish amino-terminus, Forkhead box, and C terminus relative to human FOXN3 is shown. The conserved
Sin3-binding signature (EAA within the C terminus) is marked. Putative phosphorylation sites found in five or more published phospho-proteomic surveys are
shown as well: the significance of these residues’ phosphorylation has not been established in any organism.
(B) A non-transgenic (wild-type [WT]) 7 days post-fertilization (dpf) larva and two transgenic larvae were photographed in light- and green fluorescent channels in
the left-lateral view. The Tg(fabp10a:foxn3,EGFP)z106 transgenic line overexpresses zebrafish foxn3 and EGFP, and the Tg(fabp10a:FOXN3,EGFP)z107 transgenic
line overexpresses human FOXN3 and EGFP (transcript variant -T003). The encoded EGFP protein is translated as a free (not as a fusion) protein (Provost et al.,
2007). The scale bar represents 500 mm.
(C and D) pck1 promoter activity (bioluminescence derived from assay of luciferase) in lysates prepared from 5 and 6 days post-fertilization (dpf),
never-fed Tg(pck1:Luc2,cryaa:mCherry)s952, Tg(fabp10a:foxn3,EGFP)z106; Tg(pck1:Luc2,cryaa:mCherry)s952 and Tg(fabp10a:FOXN3,EGFP)z107; and Tg(pck1:
Luc2,cryaa:mCherry)s952 larvae. p < 0.02; two-tailed Student’s t test. n = 5–7.
(E and F)Whole-body glucose levels in 6 dpfWT, Tg(fabp10a: foxn3,EGFP)z106, and Tg(fabp10a:FOXN3,EGFP)z107 larval extracts. *p < 0.02; two-tailed Student’s t
test. n = 4–5 pooled samples of ten larvae each. All values are mean ± SEM.
(G and H) Fasting blood glucose levels in WT, Tg(fabp10a: foxn3,EGFP)z106, and Tg(fabp10a:FOXN3,EGFP)z107 transgenic adult animals of both sexes after an
overnight fast.*p = 0.01; two-tailed t Student’s t test. n = 9–13.P2A-EGFP tag (Provost et al., 2007), which allowed us to identify
carriers readily (Figure 3B). Both the Tg(fabp10a:foxn3,EGFP)z106
and the Tg(fabp10a:FOXN3,EGFP)z107 transgenic lines were
crossed to the Tg(pck1:Luc2;cryaa:mCherry)s952 transgenic re-
porter line, which carries a cDNA encoding luciferase 2 under
the control of zebrafish phosphoenylpyruvate carboxykinase 1
promoter sequences (Gut et al., 2013). Phosphoenolpyruvate
carboxykinase 1 is a rate-limiting enzyme of gluconeogenesis
whose expression is strongly induced in fasting zebrafish liver;
the Tg(pck1:Luc2,cryaa:mCherry)s952 transgenic reporter line
serves as an in vivo gauge of gluconeogenic gene expression
through whole-larval extract luciferase assays (Gut et al.,2748 Cell Reports 15, 2745–2755, June 21, 20162013). Both Tg(fabp10a:foxn3,EGFP)z106; Tg(pck1:Luc2,cryaa:
mCherry)s952 and Tg(fabp10a:FOXN3,EGFP)z107; Tg(pck1:Luc2,
cryaa:mCherry)s952 transgenic lines showed increased luciferase
activity when compared to the Tg(pck1:Luc2,cryaa:mCherry)s952
line in never-fed larvae at points in development when pck1 ac-
tivity is normally induced (Figures 3C and 3D).
Paralleling this increase in gluconeogenic transcriptional re-
porter activity, we observed that whole-larval free glucose
levels, which exclusively reflect newly synthesized glucose
levels in this model (Jurczyk et al., 2011), were higher in both
Tg(fabp10a:foxn3,EGFP)z106 and Tg(fabp10a:FOXN3,EGFP)z107
transgenic larvae than in non-transgenic (wild-type [WT])
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Figure 4. FOXN3 Suppresses MYC Ex-
pression
(A) Volcano plot of differentially expressed tran-
scripts from the RNA pools (n = 3) extracted from
the livers of never-fed WT and Tg(fabp10a:
foxn3,EGFP)z106 larvae. Note the adjusted
p values are plotted on a log base 10 scale, with
higher values indicating increased significance.
(B) qPCR validation of the indicated mRNA
steady-state levels in the livers of WT and
Tg(fabp10a: foxn3,EGFP)z106 adult livers. Mean ±
SEM values are shown. *p < 0.05; two-tailed Stu-
dent’s t test (n = 5). slc2a2, solute carrier family 2
(facilitated glucose transporter), member 2.
(C) MYC transcript abundance in cryopreserved
human hepatocytes. Horizontal lines indicate the
median value. *p < 0.05; two-tailed Student’s
t test.
(D and E) The membrane shown in Figure 1E was
immunoblotted with anti-MYC IgG, and the den-
sity of the MYC band was normalized to the TUBB
band densities; this is the same blot as in Fig-
ure 1E. Horizontal lines indicate the median value.
*p = 0.019 by Mann-Whitney rank sum test after
excluding an outlier (determined using the Grub’s
test) from the AjA genotype values.
(F) Structure of the zebrafish mycb gene. A Fork-
head binding site and a MYC binding site (E box)
are located distal to the 30 UTR. The target PCR
product for the ChIP assay is underlined.
(G) qPCR analysis following ChIP with the indi-
cated antibodies was performed in WT and
Tg(fabp10a:FOXN3,EGFP)z107 livers. Fold enrich-
ment was calculated relative to the mouse IgG
levels. Mean ± SEM values are shown. n = 3.
See also Table S1 and Figure S2.controls (Figures 3E and 3F). Third, fasting blood glucose was
increased in both Tg(fabp10a:foxn3,EGFP)z106 and Tg(fabp10a:
FOXN3,EGFP)z107 transgenic adults compared to WT controls,
except in females overexpressing the zebrafish foxn3 ortholog
(Figures 3G and 3H). Collectively, these results indicate that
FOXN3 overexpression increases blood glucose through driving
enhanced liver glucose production.
FOXN3 Suppresses Expression of MYC
Previous work in cell culture established a role for FOXN3 as a
transcriptional repressor (Pati et al., 1997; Samaan et al., 2010;
Schuff et al., 2007; Scott and Plon, 2005). Specifically, human
FOXN3 and Xenopus Foxn3 bind the histone deacetylase com-
plex (HDAC) component Sin3 using a glutamyl-alanyl-alanyl
(EAA) C-terminal motif that is conserved in zebrafish Foxn3 (Fig-
ure 3A). Xenopus Foxn3 also binds the HDAC class I catalytic
subunit Rpd3 via its N-terminal 135 aminoacyl residues, a region
conserved highly among vertebrate FOXN3 ortholog (Schuff
et al., 2007). HDACs repress gene transcription by remodeling
chromatin. Thus, we posited that Foxn3 directs HDAC activity
to genes controlling liver glucose metabolism.To get a global view of the gene regulatory changes caused by
Foxn3, we performed whole-transcriptome (RNA-seq) analysis
on livers dissected from WT and Tg(fabp10a:foxn3,EGFP)z106
transgenic animals, analyzing the data with DESeq2 (Anders
and Huber, 2010). The most-upregulated gene in Tg(fabp10a:
foxn3,EGFP)z106 transgenic livers was the transgene itself (Fig-
ure 4A). The most-downregulated transcript in Tg(fabp10a:
foxn3,EGFP)z106 transgenic animals was mycb, encoding
Mycb, a transcription factor whose human and mouse orthologs
are known to regulate expression of multiple glycolytic enzymes
(Kim et al., 2004; Peterson and Ayer, 2011). Overexpression of
Myc in mouse liver causes a 25% decrease fasting blood
glucose via coordinated modulation of glycolytic and gluconeo-
genic gene expression (Kim et al., 2004; Morrish et al., 2009; Os-
thus et al., 2000; Peterson and Ayer, 2011; Valera et al., 1995).
Using RT-PCR, we confirmed the RNA-seq-detected downregu-
lation of myca and mycb and upregulation of pck1 transcript
abundance in Tg(fabp10a:foxn3,EGFP)z106 transgenic animals
(Figure 4B). Similar to pck1 induction, we found the transcript
for the liver glucose exporter Slc2a2 (Glut2) to be induced in
Tg(fabp10a:foxn3,EGFP) transgenic animals (Figure 4B).Cell Reports 15, 2745–2755, June 21, 2016 2749
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Figure 5. FOXN3 Overexpression Sup-
presses Glycolytic Gene Expression
qPCR analysis of the indicated transcripts en-
coding glycolytic enzymes in WT and Tg(fabp10a:
foxn3,EGFP)z106 livers. Horizontal lines indicate
the mean value. Two-tailed Student’s t test results
are shown. See also Figure S3.The gene expression changes seen in Tg(fabp10a:foxn3,
EGFP)z106 transgenic animals suggested that FOXN3 may regu-
late fasting glucosemetabolism by inducing gluconeogenic gene
expression and by repressing MYC-driven glycolysis. Indeed,
MYC protein is briefly induced when HepG2 cells are placed in
low-glucose medium, partially mirroring the downregulation of
FOXN3 seen under these conditions (Figures 2B, 2C, S2A, and
S2B). Thus, we measured the MYC transcript abundance
in our panel of primary human hepatocyte samples. The
rs8004664 risk allele was gene dose dependently associated
with lower MYC transcript abundance (Figure 4C; Table S1).
Immunoblot analysis of the 12 primary human hepatocytes
examined in Figures 1E and 1F revealed that the rs8004664
dose dependently decreased MYC protein abundance (Figures
4D and 4E).
Next we assessed whether FOXN3 directly regulates MYC
expression. We found a putative Forkhead binding site distal to2750 Cell Reports 15, 2745–2755, June 21, 2016the 30 UTR of human MYC, near the
MYC binding site (E-Box) annotated in
the ENCODE and JASPAR databases
(Figure S2C). Anti-FOXN3 immuno-
globulin Gs (IgGs) specifically immuno-
precipitated chromatin (ChIP) containing
the Forkhead-binding sequences from
HepG2 cells, suggesting that FOXN3
may regulateMYC expression via binding
to sequences distal to the 30 UTR ofMYC
(Figures S2D and S2E). A similar arrange-
ment of putative Forkhead binding site
and E-Box was found distal to the 30
UTR of zebrafish mycb (Figures 4F and
S4F). Compared toWT animals, we found
that Tg(fabp10a:FOXN3,EGFP)z107 trans-
genic animals showed increased binding
of both of these DNA elements by
FOXN3 and endogenous Myc proteins
(Figure 4G).
FOXN3 Overexpression
Suppresses Glycolytic Gene
Expression
In mouse livers, overexpression of
Myc induces the glycolytic transcripts
Slc2a3, which encodes glucose trans-
porter 1; Gpi1, encoding glucose-6-
phosphate isomerase 1; and Pfk1, which
encodes phosphofructokinase 1 (Osthus
et al., 2000). Further, Myc directly trans-
activates Slc2a1, Pfk1, and Eno1 (Osthuset al., 2000). We posited that overexpression of FOXN3 in zebra-
fish livers would suppress expression of MYC glycolytic targets
and tested the model by measuring the abundance of glycolytic
transcripts in fasted WT and transgenic livers. Adult Tg(fabp10a:
foxn3,EGFP)z106 transgenic livers showed decreased expression
of multiple glycolytic transcripts, including orthologs of the
mouse direct Myc targets phosphofructokinase and enolase 1.
Additionally, glucokinase and phosphoglycerate mutase 1b
transcripts were significantly decreased in Tg(fabp10a:foxn3,
EGFP)z106 transgenic livers and triosephosphate isomerase
1a and phosphoglycerate kinase 1 were nearly significantly
decreased in Tg(fabp10a:foxn3,EGFP)z106 transgenic livers
(Figure 5).
Whereas thenutritional statusof theprimaryhumanhepatocyte
donors was not known at the time of death, we examined the
abundance of glycolytic and gluconeogenic transcripts in these
samples (Figure S3). ENOLASE 1 and TRIOSEPHOSPHATE
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Figure 6. Model for How FOXN3 Sup-
presses MYC Transcription and Blunts He-
patic Glucose Utilization
During the fasted state (left), normally reduced
FOXN3 expression allows for increased MYC
expression. MYC regulates the expression of
numerous genes encoding enzymes of glycolytic
and tricarboxylic acid (TCA) cycle flux in hepato-
cytes, thereby promoting net hepatic glucose utili-
zation during the fasted state. Conversely, during
the fedstate orwhenoverexpressed in hepatocytes
either transgenically or through the rs8004664 risk
allele’sdirection (right), increasedFOXN3 represses
MYC gene expression, leading to reduced glyco-
lytic gene expression and flux through glycolysis
and the TCA cycle decrease (noted by altered
weight of arrows and circle). In parallel, gluconeo-
genesis is induced by FOXN3, as noted with red
arrows for the hypothesized route of carbon atoms.
The net effect of increased FOXN3 expression and
reduced MYC expression is increased hepatic
glucose production, leading to pathologically in-
creased blood glucose concentrations.ISOMERASE transcripts showed non-significant trends toward
decreased transcript abundance in homozygous carriers of
the rs8004664 SNP. PHOSPHOGLYCERATE MUTASE and
PHOSPHOGLYCERATE KINASE transcript abundance was sig-
nificantly decreased in homozygous carriers of the rs8004664
risk allele. Curiously, PFK1 transcript abundance was highest in
homozygous carriers of the rs8004664 risk allele. Finally, we
found thatPCK1andGLUCOSE-6-PHOSPHATASE,CATALYTIC
transcripts were not associated with the rs8004664 genotype.
Collectively, these results indicate that Foxn3 suppresses hepatic
glucose utilization, in large part, through downregulating the
glycolytic program driven by Myc (Figure 6).
DISCUSSION
The Drosophilamutant forkhead (fkh) was the first ‘‘terminal’’ ho-
meotic (body-plan-controlling) mutant identified. In contrast to
the more centrally acting homeotic mutants in the Antennapedia
and Bithorax complexes, which control ‘‘core’’ body segment
planning (i.e., head, thorax, and abdomen), fkh is a master regu-
lator of development of the extreme anterior and extreme poste-
rior of the body. Loss of fkh function gives rise to ectopic head
structures in the head and loss of tail regions that derive from pri-
mordial gut cells (J€urgens andWeigel, 1988; Weigel et al., 1989).
The Fkh protein has a signature, approximately 100 aminoacyl
residue long, DNA-binding domain called the Forkhead box
(FOX) that is highly conserved in higher-vertebrate orthologs.
There are 50 Fox family members in humans (Hannenhalli and
Kaestner, 2009). Similar to Drosophila Fkh, mouse FOXA family
members (formerly hepatocyte nuclear factors 1, 2, and 3) are
specific regulators of the development, cell architecture, and
function of another ‘‘terminal’’ structure, namely the liver (Lai
et al., 1991). Since the discovery of fkh and its mammalian ortho-
logs, numerous paralogs have been identified in vertebrates,
with Mendelian diseases, including familial cancer syndromes,
immune deficiencies, glaucoma, and speech disorders, being
caused by mutations in human FOX genes (Hannenhalli andKaestner, 2009). Several FOX family members have ‘‘neo-func-
tionalized’’ in higher vertebrates to govern specific aspects of
metabolism (Benayoun et al., 2011; Le Lay and Kaestner,
2010). For instance, FOXO is firmly established as a master
regulator of hepatic glucose production. FOXO nuclear localiza-
tion and transcriptional activity are directly inhibited by insulin
signaling, through phosphorylation of FOXO by the insulin-
effector kinase Akt; conversely, c-Jun-catalyzed phosphoryla-
tion of other sites induces FOXO nuclear localization and
activation (Pajvani and Accili, 2015).
Human FOXN3 was identified in a high-copy suppressor
screen of budding yeast checkpoint mutants (Pati et al., 1997).
Checkpoint suppressor 1 (Ches1), the first suppressor identified
in this screen, encodes FOXN3, and the protein interacts with
transcriptional repressive machinery (Scott and Plon, 2005).
Notably, FOXN3 suppresses the transcriptional activity of the
MENIN transcription factor, whose encoding gene sustains
dominant-activating mutations in the multiple endocrine
neoplasia, type 1 syndrome (Busygina et al., 2006). Because
both Xenopus embryos injected with anti-foxn3 morpholino oli-
gonucleotides and Foxn3/ mice die at early stages as a result
of craniofacial defects (Samaan et al., 2010; Schuff et al., 2007),
the role of FOXN3 in adult metabolism was not explored previ-
ously in either gain- or loss-of-function models.
We observed that hepatocyte FOXN3 transcript abundance is
nutritionally regulated (normally induced by nutrient sufficiency)
and that the risk allele of rs8004664 associated with elevated
fasting human blood glucose is also associated with higher
FOXN3 transcript and protein abundance in primary human
hepatocytes. Second, we found that overexpression of both
zebrafish foxn3 and human FOXN3 in zebrafish livers increases
gluconeogenic gene expression, larval free glucose levels, and
fasting blood glucose levels in adults when fed their normal diets.
Third, we found FOXN3 binds DNA regulatory sequence of the
glucose-utilization factor human MYC and observed enriched
binding to the orthologous Forkhead box in the zebrafish mycb
gene in intact livers, both results suggesting that FOXN3Cell Reports 15, 2745–2755, June 21, 2016 2751
represses MYC expression. Fourth, we found that FOXN3 over-
expression suppresses expression of glycolytic gene tran-
scripts, many of which are under direct transcriptional control
by MYC (Osthus et al., 2000).
Whereas we found a robust and direct suppressive role for
FOXN3 in regulating MYC expression in our zebrafish model
based on the inverse association of FOXN3 andMYC transcripts
in the 16 samples we obtained from commercial vendors, lack of
information regarding the nutritional status of these donors
(whether they received intravenous glucose or parenteral nutri-
tion at the time of death is not known) makes interpretation of
the select glycolytic and gluconeogenic transcripts difficult.
Some transcripts show the expected association with the
rs8004664 risk allele, whereas others do not. In future studies,
larger cohorts of more carefully phenotyped primary human he-
patocyte samples should be examined. Relatedly, the mecha-
nisms through which FOXN3 induces gluconeogenic expression
merit additional investigation. Specifically, it will be important to
determine what transcriptional programs are being modulated
by FOXN3 to allow for coordinated induction of gluconeogenesis
and suppression of glucose utilization. Factors other than MYC
are likely to be implicated in these processes.
Another open question that greater numbers of more thor-
oughly characterized human samples will allow us to address
is the molecular basis for the rs8004664 risk allele’s association
with greater FOXN3 expression. Whereas we did not find an an-
notated transcription factor binding site in this locus in the
ENCODE dataset (Motallebipour et al., 2009), it is formally
possible that this SNP reflects differential transcription factor
binding in a linked region (Claussnitzer et al., 2015). Furthermore,
it is conceivable that this locus regulates FOXN3 transcription
initiation, for example, by dictating preferential CpG island
methylation (Dayeh et al., 2014; Deaton and Bird, 2011). Like-
wise, pre-mRNA stability or splicing might be affected by the
rs8004664 risk allele.
Related to these molecular concerns, our findings in liver do
not exclude the possibility of other functions for FOXN3 in regu-
lating metabolism in other organs, particularly the kidney, where
the protein was detected in a systematic human immunohisto-
chemical survey (Uhle´n et al., 2015). Indeed, by analogy to the
most strongly associated diabetes gene TCF7L2, it is quite likely
that extra-hepatic functions of FOXN3 in regulating aspects of
glucose homeostasis exist (Boj et al., 2012; Dayeh et al., 2014;
Grant et al., 2006; Lyssenko et al., 2007; van Es et al., 2012;
van Vliet-Ostaptchouk et al., 2007). Preparation of conditional
loss-of-function and inducible gain-of-function foxn3 alleles will
allow dissection of the role(s) of this factor in other organs. More-
over, this approach will allow us to examine MYC-independent
FOXN3 functions in regulating metabolism.
The interface between regulation of hepatic intermediary
metabolism and neoplastic transformation also merits further
exploration in light of our study. Human hepatocellular carci-
noma relies on MYC gene amplification as a major driver of
growth (Kaposi-Novak et al., 2009). Overexpression of MYC in
the livers of mice is sufficient to cause hepatocellular carcinoma
(Murakami et al., 1993; Sandgren et al., 1989; Wu et al., 2002);
this pathological event is recapitulated in zebrafish overexpress-
ing mouse Myc in an inducible manner (Li et al., 2013).2752 Cell Reports 15, 2745–2755, June 21, 2016Conversely, even brief inactivation ofMYC is sufficient to restore
normal cell fate in mouse models of hepatocellular carcinoma
(Shachaf et al., 2004) and sarcoma (Jain et al., 2002). Most likely,
FOXN3’s regulation ofMYC targets also serves to dampenMYC-
driven hepatocyte proliferation. This hypothesis will require
similar genetic strategies to those needed to assess the role of
FOXN3 outside the liver.
Finally, future work will seek to establish the acute nutritional
and hormonal cues that regulate FOXN3 protein function,
including those factors that regulate its (potential) phosphoryla-
tion, nucleo-cytoplasmic trafficking, and protein-protein interac-
tions. Such knowledge may reveal the interaction of this factor
with known signaling pathways that regulate hepatocyte func-
tion. Similarly, comprehensive evaluation of FOXN3’s direct
and indirect targets might disclose potentially druggable targets
to treat type 2 diabetes mellitus.
EXPERIMENTAL PROCEDURES
Cryopreserved Human Hepatocytes
Cryopreserved human hepatocytes were purchased from Zen-Bio (ZBH) and
Triangle Research Labs (HUM). The lot numbers, phenotypes, and genotypes
of individual samples are listed in Table S1. Hepatocytes were thawed and ali-
quoted for RNA, DNA, and protein extraction.
Zebrafish Fasting Studies and Blood Chemistry
The Institutional Animal Care and Use Committee of the University of Utah
approved all studies. Three-month-old fish were fed standard zebrafish diets
supplemented with brine shrimp. Animals were housed at 28C and exposed
to 14 hr light and 10 hr of darkness per day. Thirty minutes after lights were
turned on each morning, fish were euthanized by immersing in ice water (Wil-
son et al., 2009) and blood was drawn from the caudal vein. Blood glucose
levels weremeasured using a glucosemeter (Contour; Bayer). Livers were har-
vested, frozen in liquid nitrogen, and stored at 80C.
Generation of Transgenic Fish
Tol2 transposon-mediated transgenesis was used to generate the Tg(fapb10a:
foxn3,EGFP)z106 and Tg(fapb10a:FOXN3,EGFP)z107 (Kwan et al., 2007). Three
founders were recovered for both the transgenic lines, and all the lines had
equally bright EGFP fluorescence. Single integration was evidenced by the
50% Mendelian ratio of carriers obtained after outcrossing the founders with
the WT strain WIK. The primers used to generate the Gateway entry clones
are listed in Table S2. The fabp10a promoter that drives liver-specific expres-
sion was described previously (Her et al., 2003).
Cell Culture
HepG2 cells were purchased from ATCC and grown in Eagle’s minimum
essential medium supplemented with 10% fetal bovine serum (FBS) and anti-
biotics. For the serum deprivation experiments, cells were grown in complete
medium for 48 hr and then deprived of serum as indicated.
Rat Fasting Study
The Institutional Animal Care and Use Committee of the University of Utah
approved all studies. Eight-month-old male rats were fed a standard chow
diet (Harlan Teklad TD.8640). Where indicated, they were fasted for 15 hr prior
to treatment with isoflurane anesthesia and cervical dislocation. Livers were
harvested, quickly frozen in liquid nitrogen, and stored at 80C.
Immunoblotting
Cryopreserved hepatocytes, HepG2 cells, or livers were sonicated in 400 ml
radio-immunoprecipitation assay (RIPA) buffer supplemented with protease
and phosphatase inhibitors (Roche Complete MINI and PhosSTOP). Protein
concentration was determined using the bicinchoninic acid method (Pierce;
ThermoFisher Scientific). Fifteen to thirty micrograms of protein from each
lysate was separated by SDS-PAGE using precast Tris-Glycine (Bio-Rad) or
Bis-Tris (Thermo Fisher) gels, transferred to nitrocellulose or polyvinylidene
fluoride (PVDF) membranes and detected with commercially available anti-
bodies. The antibodies used were anti-FOXN3 from Abgent (AP19255B);
anti-b-tubulin (TUBB) from Abcam (ab6046); and anti-c-Myc (clone 9E10)
from Thermo Fisher. ImageJwas used to quantify the relative density of protein
bands. Following exposure, X-ray films of immunoblots were scanned. The im-
ages were inverted, and the raw integral density was quantified for each band.
Then, the raw integral density of each FOXN3 or c-MYC band was divided by
the raw integral density of the corresponding TUBB band.
RNA Isolation, cDNA Synthesis, and qPCR
Total RNA was isolated from cryopreserved hepatocytes, HepG2 cells, or rat
livers using a standard TRIzol method (Thermo Fisher). mRNA in 2 mg of total
RNA was converted to cDNA using oligo(dT) primer and random hexamers ac-
cording to the manufacturer’s instructions (Clontech EcoDry Premix). The
primers for all the measured transcripts are listed in Table S2. To measure
the steady-state mRNA abundance ofMYC transcript, we used a predesigned
assay (Hs.PT.58.26770695; Integrated DNA Technologies). For thermal
cycling and fluorescence detection, an Agilent Technologies Stratagene MX
3000P machine was used (Genomics Core Facility, University of Utah). The
threshold (Ct) values of fluorescence for each readout was normalized to cor-
responding Ct values from ef1a (zebrafish liver), HMBS (HepG2 cells), and
HMBS (cryopreserved human hepatocytes), and fold change was calculated
using the DDCt method (Pfaffl, 2001).
DNA Isolation, PCR, and Genotyping
Following TRIzol RNA extraction, DNA was precipitated from the remaining
interphase and phenol phase following manufacturer’s instructions (Thermo
Fisher). DNA was precipitated with ethanol, and the resulting pellet was
washed with 0.1 M sodium citrate and 75% ethanol. DNA was resuspended
in 8 mM NaOH. Twenty nanograms of DNA were used as template in a PCR
reaction to amplify a 257-bp product surrounding the rs8004664 SNP. The
PCR products were extracted from an agarose gel after electrophoresis, puri-
fied, and Sanger sequenced.
RNA-Seq Analysis
Total RNA was extracted from six pools of approximately 30 livers dissected
from 7 days post-fertilization (dpf) Tg(fapb10a:foxn3,EGFP)z106 and non-trans-
genic siblings using a DirectZol RNA miniprep kit (Zymo Research). Isolated
RNA was run on a Bioanalyzer 2100 Nano Chip (Agilent) to confirm RNA quan-
tity and quality. Illumina TruSeq Stranded Total RNA Sample Prep Kit was used
to prepare the library. Samples were barcoded as transgenic versus WT, and
single-end 50-bp reads were generated on a Hiseq 2000 machine. Analysis
was performed as described previously (Hill et al., 2013). Reads were aligned
to the genome using NovoAlign version 3.02.07 and a custom index created
using the Zv9 genome build, including unassigned scaffolds, and annotated
splice junctions generated by the MakeTranscriptome command in the
USeq package (version 8.7.0). Splice junction reads were then converted to
genomic coordinates using the SamTranscriptomeParser command in USeq
and assigned to genes using the Rsubread package for the R programming
language (Liao et al., 2013) and the Ensembl RNA annotation. Differential
gene expression analysis was performed on the resulting count table using
DESeq2 (Love et al., 2014).
In Vivo Luciferase Reporter Assay
Luciferase reporter assays were carried out as described previously (Gut et al.,
2013). Heterozygous carriers of Tg(pck1:Luc2,cryaa:mCherry)s952 were
crossed to heterozygous carriers of Tg(fapb10a:foxn3,EGFP)z106 and
Tg(fapb10a:FOXN3,EGFP)z107. Larvae carrying both transgenes (as scored
by green fluorescent livers and red fluorescent eyes) and control larvae
Tg(pck1:Luc2,cryaa:mCherry)s952 (red fluorescent eyes only) were selected.
Four larvae from each group were placed in a single well of a 96-well, opaque
white microplate (PerkinElmer) and anesthetized with Tricaine. One hundred
microliters of Steady-Glo luciferase assay solution (Promega) was added to
disintegrate the larvae and solubilize luciferase. The plates were incubated
for 30 min, and a plate reader (BioTek) was used to measure luminescence.Total Whole-Body Glucose in Larvae
A colorimetry-based enzymatic detection kit (Biovision) was used to measure
the total whole-body glucose in larvae (Jurczyk et al., 2011). Four replicate
pools of ten larvae were homogenized using a sonicator and centrifuged.
The supernatant was collected and used for measuring glucose and protein.
ChIP
Chromatin for ChIP was prepared by fixing HepG2 cells and zebrafish livers in
1% formaldehyde for 12 min followed by quenching with 0.125 M glycine for
5 min. A previously described protocol for the ChIP assays for Myc was fol-
lowed (Barrilleaux et al., 2013). In brief, 5–6 3 106 fixed HepG2 cells or
50 mg of fixed zebrafish liver were lysed in the cell lysis buffer and centrifuged
to collect the pelleted nuclear fraction, which was then lysed in nuclear lysis
buffer using sonication. Reactions were performed using 3 mg of anti-FOXN3
or anti-MYC IgGs and 20 ml of Protein G magnetic beads (Thermo Fisher).
Washes were performed using IP wash buffers, and the resulting DNA was pu-
rified using Bioneer PCR clean up kit following themanufacturer’s instructions.
ChIP experiments were repeated in triplicate. Five nanograms of DNA were
used as a template in the qPCR reactions. Primers are listed in Table S2.
Data and Statistical Analysis
Data were analyzed with SigmaPlot 13 (Systat Software). Data displayed are
mean ± SEM. Pairwise comparisons between groups (for example, WT versus
transgenic) were made using paired or unpaired Student’s t tests, as appro-
priate. For time series or multiple group comparisons, one-way ANOVA was
used, as appropriate. Unless otherwise indicated, p < 0.05 was considered
to be statistically significant.
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this study is GEO:
GSE80003.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and two tables and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2016.05.056.
AUTHOR CONTRIBUTIONS
Conceptualization, S.K. and A.S.; Methodology, S.K., E.K.Z., and J.T.H.;
Investigation, S.K., E.K.Z., J.T.H., and A.S.; Writing – Original Draft, S.K. and
A.S.; Writing – Reviewing & Editing, S.K., E.K.Z., J.T.H., H.J.Y., and A.S.; Fund-
ing Acquisition, H.J.Y. and A.S.; Resources, S.K., J.T.H., H.J.Y., and A.S.; Su-
pervision, A.S.
ACKNOWLEDGMENTS
This study was supported by grants from the NIH (K08DK078605 and
R01DK096710 to A.S. and UM1HL098160 to H.J.Y.) and funds from the Uni-
versity of Utah Diabetes and Metabolism Center (to A.S.), the University of
Utah Molecular Medicine Program (to A.S.), and the Department of Internal
Medicine, University of Utah School of Medicine (to A.S.). We thank Philipp
Gut and Didier Y.R. Stainier for sharing the pck1 reporter strain, Kristen
Kwan for sharing reagents, and Simon J. Fisher for comments on the
manuscript.
Received: March 3, 2016
Revised: April 27, 2016
Accepted: May 13, 2016
Published: June 9, 2016
REFERENCES
Anders, S., and Huber,W. (2010). Differential expression analysis for sequence
count data. Genome Biol. 11, R106.Cell Reports 15, 2745–2755, June 21, 2016 2753
Barrilleaux, B.L., Cotterman, R., and Knoepfler, P.S. (2013). Chromatin immu-
noprecipitation assays for Myc andN-Myc.MethodsMol. Biol. 1012, 117–133.
Benayoun, B.A., Caburet, S., and Veitia, R.A. (2011). Forkhead transcription
factors: key players in health and disease. Trends Genet. 27, 224–232.
Boj, S.F., van Es, J.H., Huch, M., Li, V.S., Jose´, A., Hatzis, P., Mokry, M., Hae-
gebarth, A., van den Born, M., Chambon, P., et al. (2012). Diabetes risk gene
andWnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult
metabolic demand. Cell 151, 1595–1607.
Bonnefond, A., and Froguel, P. (2015). Rare and common genetic events in
type 2 diabetes: what should biologists know? Cell Metab. 21, 357–368.
Busygina, V., Kottemann, M.C., Scott, K.L., Plon, S.E., and Bale, A.E. (2006).
Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor
CHES1 in DNA damage response. Cancer Res. 66, 8397–8403.
Claussnitzer, M., Dankel, S.N., Kim, K.-H., Quon, G., Meuleman, W., Haugen,
C., Glunk, V., Sousa, I.S., Beaudry, J.L., Puviindran, V., et al. (2015). FTO
obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med.
373, 895–907.
Dayeh, T., Volkov, P., Salo¨, S., Hall, E., Nilsson, E., Olsson, A.H., Kirkpatrick,
C.L., Wollheim, C.B., Eliasson, L., Ro¨nn, T., et al. (2014). Genome-wide DNA
methylation analysis of human pancreatic islets from type 2 diabetic and
non-diabetic donors identifies candidate genes that influence insulin secre-
tion. PLoS Genet. 10, e1004160.
Deaton, A.M., and Bird, A. (2011). CpG islands and the regulation of transcrip-
tion. Genes Dev. 25, 1010–1022.
Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A.,
Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al.
(2006). Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of
type 2 diabetes. Nat. Genet. 38, 320–323.
Grarup, N., Sandholt, C.H., Hansen, T., and Pedersen, O. (2014). Genetic sus-
ceptibility to type 2 diabetes and obesity: from genome-wide association
studies to rare variants and beyond. Diabetologia 57, 1528–1541.
Gut, P., Baeza-Raja, B., Andersson, O., Hasenkamp, L., Hsiao, J., Hesselson,
D., Akassoglou, K., Verdin, E., Hirschey, M.D., and Stainier, D.Y.R. (2013).
Whole-organism screening for gluconeogenesis identifies activators of fasting
metabolism. Nat. Chem. Biol. 9, 97–104.
Hannenhalli, S., and Kaestner, K.H. (2009). The evolution of Fox genes and
their role in development and disease. Nat. Rev. Genet. 10, 233–240.
Her, G.M., Chiang, C.-C., Chen, W.-Y., and Wu, J.-L. (2003). In vivo studies of
liver-type fatty acid binding protein (L-FABP) gene expression in liver of trans-
genic zebrafish (Danio rerio). FEBS Lett. 538, 125–133.
Hill, J.T., Demarest, B.L., Bisgrove, B.W., Gorsi, B., Su, Y.C., and Yost, H.J.
(2013). MMAPPR: mutation mapping analysis pipeline for pooled RNA-seq.
Genome Res. 23, 687–697.
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg,
C.D., Bishop, J.M., and Felsher, D.W. (2002). Sustained loss of a neoplastic
phenotype by brief inactivation of MYC. Science 297, 102–104.
Jurczyk, A., Roy, N., Bajwa, R., Gut, P., Lipson, K., Yang, C., Covassin, L.,
Racki, W.J., Rossini, A.A., Phillips, N., et al. (2011). Dynamic glucoregulation
and mammalian-like responses to metabolic and developmental disruption
in zebrafish. Gen. Comp. Endocrinol. 170, 334–345.
J€urgens, G., andWeigel, D. (1988). Terminal versus segmental development in
the Drosophila embryo: the role of the homeotic gene fork head. Rouxs Arch.
Dev. Biol. 197, 345–354.
Kaposi-Novak, P., Libbrecht, L., Woo, H.G., Lee, Y.-H., Sears, N.C., Cou-
louarn, C., Conner, E.A., Factor, V.M., Roskams, T., and Thorgeirsson, S.S.
(2009). Central role of c-Myc duringmalignant conversion in human hepatocar-
cinogenesis. Cancer Res. 69, 2775–2782.
Kim, J.W., Zeller, K.I., Wang, Y., Jegga, A.G., Aronow, B.J., O’Donnell, K.A.,
and Dang, C.V. (2004). Evaluation of myc E-box phylogenetic footprints in
glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell. Biol.
24, 5923–5936.
Kwan, K.M., Fujimoto, E., Grabher, C., Mangum, B.D., Hardy, M.E., Campbell,
D.S., Parant, J.M., Yost, H.J., Kanki, J.P., and Chien, C.-B. (2007). The Tol2kit:2754 Cell Reports 15, 2745–2755, June 21, 2016a multisite gateway-based construction kit for Tol2 transposon transgenesis
constructs. Dev. Dyn. 236, 3088–3099.
Lai, E., Prezioso, V.R., Tao, W.F., Chen, W.S., and Darnell, J.E., Jr. (1991). He-
patocyte nuclear factor 3 alpha belongs to a gene family in mammals that is
homologous to the Drosophila homeotic gene fork head. Genes Dev. 5,
416–427.
Le Lay, J., and Kaestner, K.H. (2010). The Fox genes in the liver: from organ-
ogenesis to functional integration. Physiol. Rev. 90, 1–22.
Li, Z., Zheng, W., Wang, Z., Zeng, Z., Zhan, H., Li, C., Zhou, L., Yan, C., Spits-
bergen, J.M., and Gong, Z. (2013). A transgenic zebrafish liver tumor model
with inducible Myc expression reveals conserved Myc signatures with
mammalian liver tumors. Dis. Model. Mech. 6, 414–423.
Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate
and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Lyssenko, V., Lupi, R., Marchetti, P., Del Guerra, S., Orho-Melander, M., Almg-
ren, P., Sjo¨gren, M., Ling, C., Eriksson, K.F., Lethagen, A.L., et al. (2007).
Mechanisms by which common variants in the TCF7L2 gene increase risk of
type 2 diabetes. J. Clin. Invest. 117, 2155–2163.
Manning, A.K., Hivert, M.F., Scott, R.A., Grimsby, J.L., Bouatia-Naji, N., Chen,
H., Rybin, D., Liu, C.T., Bielak, L.F., Prokopenko, I., et al.; DIAbetes Genetics
Replication And Meta-analysis (DIAGRAM) Consortium; Multiple Tissue Hu-
man Expression Resource (MUTHER) Consortium (2012). A genome-wide
approach accounting for body mass index identifies genetic variants influ-
encing fasting glycemic traits and insulin resistance. Nat. Genet. 44, 659–669.
Morrish, F., Isern, N., Sadilek, M., Jeffrey, M., and Hockenbery, D.M. (2009).
c-Myc activates multiple metabolic networks to generate substrates for cell-
cycle entry. Oncogene 28, 2485–2491.
Motallebipour, M., Ameur, A., Reddy Bysani, M.S., Patra, K., Wallerman, O.,
Mangion, J., Barker, M.A., McKernan, K.J., Komorowski, J., and Wadelius,
C. (2009). Differential binding and co-binding pattern of FOXA1 and FOXA3
and their relation to H3K4me3 in HepG2 cells revealed by ChIP-seq. Genome
Biol. 10, R129.
Murakami, H., Sanderson, N.D., Nagy, P., Marino, P.A., Merlino, G., and Thor-
geirsson, S.S. (1993). Transgenic mouse model for synergistic effects of nu-
clear oncogenes and growth factors in tumorigenesis: interaction of c-myc
and transforming growth factor a in hepatic oncogenesis. Cancer Res. 53,
1719–1723.
Osthus, R.C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Won-
sey, D., Lee, L.A., and Dang, C.V. (2000). Deregulation of glucose transporter 1
and glycolytic gene expression by c-Myc. J. Biol. Chem. 275, 21797–21800.
Pajvani, U.B., and Accili, D. (2015). The new biology of diabetes. Diabetologia
58, 2459–2468.
Pati, D., Keller, C., Groudine, M., and Plon, S.E. (1997). Reconstitution of a
MEC1-independent checkpoint in yeast by expression of a novel human fork
head cDNA. Mol. Cell. Biol. 17, 3037–3046.
Peterson, C.W., and Ayer, D.E. (2011). An extended Myc network contributes
to glucose homeostasis in cancer and diabetes. Front. Biosci. (Landmark Ed.)
16, 2206–2223.
Pfaffl, M.W. (2001). A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res. 29, e45.
Provost, E., Rhee, J., and Leach, S.D. (2007). Viral 2A peptides allow expres-
sion of multiple proteins from a single ORF in transgenic zebrafish embryos.
Genesis 45, 625–629.
Samaan, G., Yugo, D., Rajagopalan, S., Wall, J., Donnell, R., Goldowitz, D.,
Gopalakrishnan, R., and Venkatachalam, S. (2010). Foxn3 is essential for
craniofacial development in mice and a putative candidate involved in human
congenital craniofacial defects. Biochem. Biophys. Res. Commun. 400,
60–65.
Sandgren, E.P., Quaife, C.J., Pinkert, C.A., Palmiter, R.D., and Brinster, R.L.
(1989). Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4,
715–724.
Sanghera, D.K., and Blackett, P.R. (2012). Type 2 diabetes genetics: beyond
GWAS. J. Diabetes Metab. 3, 6948.
Schlegel, A., and Gut, P. (2015). Metabolic insights from zebrafish genetics,
physiology, and chemical biology. Cell. Mol. Life Sci. 72, 2249–2260.
Schuff, M., Ro¨ssner, A., Wacker, S.A., Donow, C., Gessert, S., and Kno¨chel,
W. (2007). FoxN3 is required for craniofacial and eye development of Xenopus
laevis. Dev. Dyn. 236, 226–239.
Scott, K.L., and Plon, S.E. (2005). CHES1/FOXN3 interacts with Ski-interacting
protein and acts as a transcriptional repressor. Gene 359, 119–126.
Shachaf, C.M., Kopelman, A.M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S.,
Bachmann, M.H., Borowsky, A.D., Ruebner, B., Cardiff, R.D., et al. (2004).
MYC inactivation uncovers pluripotent differentiation and tumour dormancy
in hepatocellular cancer. Nature 431, 1112–1117.
Uhle´n, M., Fagerberg, L., Hallstro¨m, B.M., Lindskog, C., Oksvold, P., Mardino-
glu, A., Sivertsson, A˚., Kampf, C., Sjo¨stedt, E., Asplund, A., et al. (2015). Pro-
teomics. Tissue-based map of the human proteome. Science 347, 1260419.
Valera, A., Pujol, A., Gregori, X., Riu, E., Visa, J., and Bosch, F. (1995). Evi-
dence from transgenic mice that myc regulates hepatic glycolysis. FASEB J.
9, 1067–1078.van Es, J.H., Haegebarth, A., Kujala, P., Itzkovitz, S., Koo, B.K., Boj, S.F., Korv-
ing, J., van den Born, M., van Oudenaarden, A., Robine, S., and Clevers, H.
(2012). A critical role for the Wnt effector Tcf4 in adult intestinal homeostatic
self-renewal. Mol. Cell. Biol. 32, 1918–1927.
van Vliet-Ostaptchouk, J.V., Shiri-Sverdlov, R., Zhernakova, A., Streng-
man, E., van Haeften, T.W., Hofker, M.H., and Wijmenga, C. (2007). As-
sociation of variants of transcription factor 7-like 2 (TCF7L2) with suscep-
tibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 50,
59–62.
Weigel, D., J€urgens, G., K€uttner, F., Seifert, E., and Ja¨ckle, H. (1989). The ho-
meotic gene fork head encodes a nuclear protein and is expressed in the ter-
minal regions of the Drosophila embryo. Cell 57, 645–658.
Wilson, J.M., Bunte, R.M., and Carty, A.J. (2009). Evaluation of rapid cooling
and tricaine methanesulfonate (MS222) as methods of euthanasia in zebrafish
(Danio rerio). J. Am. Assoc. Lab. Anim. Sci. 48, 785–789.
Wu, Y., Renard, C.A., Apiou, F., Huerre, M., Tiollais, P., Dutrillaux, B., and
Buendia, M.A. (2002). Recurrent allelic deletions at mouse chromosomes 4
and 14 in Myc-induced liver tumors. Oncogene 21, 1518–1526.Cell Reports 15, 2745–2755, June 21, 2016 2755
